Peripheral blood stem cell transplantation after reducedintensity conditioning (RIC-PBSCT) regimen is an alternative to conventional regimens with less immediate toxicity. Since immune recovery is of crucial importance for the control of infections, we retrospectively studied the recovery of T-, B-and NK cell subsets in 20 consecutive patients undergoing RIC-PBSCT. We also studied the thymic output using T-cell receptor excision circle assay. Engraftment was rapid and few infectious complications were seen: three early (before 2.5 months) cases of asymptomatic cytomegalovirus reactivation, two late Gram-negative bacterial infections and no fungal infection. While CD4 þ T-cell reconstitution was slow, CD8 þ T-cell counts were close to normal values at 4 months. Median CD19 þ B-cell counts reached normal values at 11 months. Rapid CD56 þ NK cell reconstitution was noticed as early as 1.5 months. Low T-cell receptor excision circle numbers and preponderance of memorytype subsets among T cells further suggested that CD8 þ T-cell reconstitution resulted predominantly from peripheral expansion and that thymic-dependent reconstitution was severely impaired. In conclusion, large peripheral Tcell expansion may compensate for late thymic-dependent lymphopoiesis, and may, with other factors such as NK and B-cell reconstitution and careful antiinfectious prophylaxis, help limit the incidence of severe infections after RIC-PBSCT. Bone Marrow Transplantation (2005) 35, 859-868.
Hematopoietic stem cell transplantation (HSCT) after reduced-intensity conditioning (RIC) is less toxic than conventional allogeneic HSCT for patients with selected malignant hematologic disorders or solid tumors. [1] [2] [3] [4] [5] The reduced mucosal toxicity of RIC and the shorter period of neutropenia are associated with decreased risk of early bacteremia, but identical risk of fungal infections compared to myeloablative conditioning regimen. [6] [7] [8] Similarly, the long-term overall incidence of viral infections after RIC-HSCT, especially CMV disease (leading to significant mortality and mortality rate in HSCT 9, 10 ), remains comparable to myeloablative HSCT. However, the occurrence of CMV disease seems to be delayed beyond the 100 first days post transplant. 11 Accelerated CD4 þ T-cell recovery decreases the infection risk after HSCT.
12 CD4 þ T-cell reconstitution is performed through an early peripheral expansion of graft mature memory T cells 13, 14 followed by a central output of naı¨ve thymic emigrants. 15, 16 Different studies evaluating the impact of the source of graft in the allogeneic myeloablative setting emphasize a faster T-cell recovery using peripheral blood stem cells (PBSC) as compared with bone marrow. [17] [18] [19] [20] We analyzed 20 consecutive patients receiving RIC and unmanipulated allogeneic PBSC transplantation (RIC-PBSCT) and monitored immunophenotypic features of circulating lymphoid contingent and thymic emigrants (TREC (thymic TCR rearrangement excision circle)) up to 3.5 years.
Patients and methods

Recipients
In all, 20 patients receiving an allogeneic RIC-PBSCT between November 1999 and May 2003 were retrospectively analyzed after approval by the local ethics committee. Pre-transplant characteristics are summarized in Table 1 . All patients were ineligible for conventional allogeneic transplantation. Eight patients were at high-risk of CMV disease (donor-positive or -negative/recipient CMV seropositive), four patients at intermediate-risk (donor positive/ recipient seronegative) and then eight patients at low-risk (donor and recipient seronegative). 11 Five patients (# 1, 2, 3, 4, 9) received donor lymphocyte infusions (DLI) after transplantation: four patients received two subsequent DLI and one patient a single DLI. The median time from transplant to reinfusion was 106 days (84-393) for the first DLI and 180 days (120-240) for the second ( Table 2 ). The reasons for DLI were, respectively: three patients with relapse and two patients with mixed chimerism for 1st DLI, one patient with relapse and three patients with mixed chimerism for the 2nd DLI. All patients receiving DLIs were included in the T-cell recovery analyses, except patient 1 (Figure 2a and b) and patient 3 (Figures 2c-e and 3a).
Donors and graft characteristics
Donor characteristics are summarized in Table 1 . In all, 18 donors were HLA-genoidentical siblings and two were HLA-matched unrelated volunteer donors (donor of recipient # 11: HLA class I and class II identical; donor of recipient # 7: one HLA-DP mismatch). HLA class I -HLA-A,-B,-C -and HLA class II -HLA-DR, DP, DQgenotyping were performed with sequence-specific primer polymerase chain reaction (PCR). PBSCs were collected following mobilization with granulocyte colony-stimulating factor 5 mg/kg twice daily subcutaneous for 5 days. Leukapheresis was performed on day 57 day 6 to reach at least 4 Â 10 6 CD34 þ cells/kg. All leukapheresis were performed with the Spectra system (COBE, Denver, CO, USA). The median number of infused CD34 þ cells and CD3 þ cells were, respectively, 7.6 Â 10 6 /kg (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , 168.3 Â 10 6 /kg (45.5-481.3) ( Table 1) .
Preparative regimens
Seven patients received a combination of a single dose total body irradiation (200 cGy; day À1 or day À5) and fludarabine 30 mg/m 2 once daily from day À4 to day À2 with, for one patient (11), ATG (MTIX Sangstat SAS Lyon, France) 2.5 mg/kg daily from day À4 to day À3. A total of 13 patients received fludarabine-based regimen administered at 30 mg/m 2 once daily from day À4 to day À2, of which 11 patients received oral busulfan 2 mg/kg once daily from day À4 to À3 and ATG (with the same schedule as described above), one received cyclophosphamide 30 mg/kg once daily from day À4 to day À3 associated with ATG and one received idarubicin (21 mg/m 2 , day À12 and day À11) and cytarabine (2 g/m 2 , from day À5 to day À2).
Graft-versus-host disease (GvHD) prophylaxis
GvHD prophylaxis consisted of either oral CSA 4.5 mg/kg/ day peritoneally (p.o.) from day À3 (adapted to pharmacokinetic assays -laboratory normal values: 100-300 ng/ml) with mycophenolate mofetil 2 g daily from day À1 to day þ 28 (n ¼ 9 patients), or CSA intravenously (i.v.) 2.5 mg/kg twice daily day À3 to day À1, and then tapered to 3 mg/kg once daily (adapted to pharmacokinetic assays) with (n ¼ 2) or without (n ¼ 9) methotrexate 15 mg/m 2 at day 1 and 10 mg/m 2 at day 3 and day 6 post transplant. In the absence of GvHD, CSA was tapered at 3 months from 10% every 10-15 days, according to chimerism analysis and stopped after about 6 months. Immune recovery after reduced-intensity conditioning regimen F Larosa et al
Infectious supportive care
All patients received oral bacterial prophylaxis using phenoxymethylpenicilline 3 MU/day or spiramycine 3 MU/day, viral prophylaxis with valaciclovir p.o. 500 mg/twice daily when donor and recipient (D/R) were serologically CMV negative and 1 g Â 3/day when D and/or R was serologically CMV positive. Oral fluconazole 200 mg daily was administered for fungal prophylaxis. Finally, all patients received pentamidine inhalation monthly or oral cotrimoxazole daily to prevent Pneumocystis carinii. Immunoglobulin levels were checked before and weekly after transplantation. Supplemental polyvalent immunoglobulins G (Tegeline s , LFB les Ulis, Courtaboeuf, France) were infused (400 mg/kg) when level of immunoglobulin G was lower than 5 g/l. Bacterial, fungal and viral prophylaxis was started at day À1 and stopped, in the absence of GvHD and of immunosuppressive regimen, after about 6 months.
Blood CMV pp65 antigenemia was assessed weekly until withdrawal of immunosuppression as described 21 (CINAkit, Argene Biosoft, France). A patient was considered positive when having at least two infected cells out of 2 Â 10 5 leukocytes. Patients with two consecutive positive CMV antigenemia received pre-emptive therapy with ganciclovir 5 mg/kg i.v. twice daily or 3 g p.o. daily for 2 weeks, or longer if the assay remained positive. CMV disease was defined as described previously. 11 Fungal infections were assessed weekly at least until withdrawal of immmunosuppression and classified according to the international consensus. 22 Concerning bacterial infections, central blood cultures were performed only in case of fever greater than 381C or clinical signs of infections in hospitalized patients to identify the etiology of bacteria and fungal infections and routine urine samples were assessed weekly in hospitalized patients for bacteria and fungal infections.
Discharged patients were followed up weekly for CMV and fungal Aspergillosis infections at least until withdrawal of immunosuppressive treatment. Oral empiric broad-spectrum antibiotics (ciprofloxacin and cefpodoxime proxetil) were begun at home in case of temperature greater than 381C.
Cell counts and analysis of cell surface markers
Blood lymphocyte counts were routinely evaluated using a HST 201 automate (Sysmex, Kobe, Japan) at different time periods after transplantation: M þ 1. Immune recovery after reduced-intensity conditioning regimen F Larosa et al
TREC quantification
The signal-joint TREC were retrospectively quantified in PBMC by means of real-time quantitative PCR with Taqman assays. The PCR primer sequences were as follows: sense, 5 0 -GCC AGC TGC AGG GTT TAG G- Immune recovery after reduced-intensity conditioning regimenprobe. One cycle of denaturation/enzyme activation (951C for 10 min) was followed by 50 cycles of amplification (941C for 30 s, 601 for 30 s), performed on LightCycler (Roche Diagnostics, Meylan, France). A series of standard dilutions of a plasmid containing the signal-joint breakpoint was used to quantitate TREC in each patient and control DNA sample. Cycle threshold was assessed using the second derivative method with the LightCycler software 3.5.3. Each DNA sample was run in duplicate. Quantification of a reference gene (GAPDH) was carried out in the same conditions with primers and probes as follows: GAPDH1, 5 0 -GAG ATG GTG CAG AAC CTC AT-3 0 ; primer GAPDH2, 5 0 -CCA AAT TCA TCG AAA TAG CC-3 0 ; and GAPDH probe, 5 0 -FAM-CAC CAC AGA GGC CCA AGG TC-TAMRA-3 0 . DNA samples were analyzed at M þ 7.5 and M þ 11 post transplantation. Results were expressed as the mean of duplicate TREC copies number normalized by GAPDH gene copies number.
Chimerism analysis
Chimerism analyses were performed on marrow and peripheral blood nucleated cells at M þ 2.5, M þ 7.5 and M þ 11 post transplantation, as well as on sorted CD3 þ cells. Percentages of donor-host chimerism for recipients were based upon semiquantitative PCR-based amplification of short tandem repeat (STR) sequences unique to donors and hosts. 24 Quantification of chimerism using STR was performed after GeneScan (Applied Biosystem; Courtaboeuf, France) software analysis of the respective fluorescence peak intensity of donors' and recipients' informative STR loci.
Statistical analysis
Given the low number of patients included in the study, the cohort of patients was not censored for clinical and biological events that could influence the immunoreconstitution, such as preparative regimen, immunosuppressive regimen, GvHD, relapse or DLI, in order to perform an overall analysis of immunoreconstitution after RIC-PBSCT. Descriptive statistics, log-rank test, paired Student's t-test or Wilcoxon's signed rank test (depending on Gaussian or non-Gaussian distribution of values) were performed with SPSS software (SPSS France, Paris, France) or with Sigma Stat software (Jandel Scientific, Erkrath, Germany). Survival curves were analyzed according to Kaplan-Meier method (SPSS France).
Results
Survival and engraftment
Median times to neutrophil reconstitution (4500 neutrophils/ml) and platelet reconstitution (420 000 platelets/ml) were 8 days (0-15) and 12 days (0-18), respectively. At the end of the study, 11 patients were still alive with a median follow-up of 445 days (208-1279): six were in complete response (CR), two in partial response (PR) and three in progressive disease (PD). Relapse occurred at a median time of 210 days (70-280) in four patients out of nine (44%) who were in PR or CR at the time of transplantation, while seven patients out of 11 (64%) who were in PD at the time of transplantation had an uncontrolled disease noticed at a median time of 100 days (20-595). Three patients out of nine (33%) who were in PR or CR at the time of transplantation died at a median time of 480 days (308-507) from GvHD (n ¼ 1) or relapse (n ¼ 2) and six patients out of 11 (55%) who were in PD at the time of transplantation died at a median time of 161 days (120-343) from progression of their disease (n ¼ 3), GvHD (n ¼ 2) and acute respiratory distress syndrome (n ¼ 1). No overall survival difference was observed between patients who were in PD and those who were in PR or CR at the time of transplantation (Kaplan-Meier test, P ¼ 0.131), possibly due to the low number of patients included in this cohort. Acute (X grade II) GvHD occurred among 13 patients (65%) with a median time of 38 days (9-93), while extensive chronic GvHD (cGvHD) occurred in four patients (20%) with a Immune recovery after reduced-intensity conditioning regimen F Larosa et al median time of 142 days (100-160). Chimerism analysis showed that the median percentage of cells from donor origin within sorted CD3 þ cells were 89% (14-100%, n ¼ 18/20 evaluable patients) ( Table 2 ), 100% (76-100; n ¼ 12/16 evaluable patients) and 100% (46-100; n ¼ 6/13 evaluable patients) at M þ 2.5, M þ 7.5 and M þ 11, respectively.
Infectious complications
We observed only two late severe bacterial infections with Gram-negative bacteria: one patient developed Serratia bacteremia on day 127 and died on day 128 of progressive lymphoma. The second patient (15) with developed Pseudomonas bacteremia on day 135 and died on day 143 in of progressive AML. Three patients (15%) developed asymptomatic CMV antigenemia without CMV disease on days 30-80 ( Table 2 ). All patients responded to pre-emptive treatment with ganciclovir. Furthermore, no EBV-induced lymphoproliferation was observed.
One patient (16) had a history of invasive pulmonary aspergillosis 4 months before transplantation. On voriconazole prophylaxis, no reactivation was observed after transplantation.
Immune reconstitution
Median total lymphocyte counts (Figure 1a ) increased during the first months post transplant and reached the normal values of healthy controls at 18 months. Median CD3 þ cell counts also increased during the first months post transplant and were close to normal values at M þ 18 (Figure 1b) . No patient achieved normal CD4 þ cell counts during the study period (Figure 1c) , and only 2/12 patients at M þ 7.5 and 2/5 patients at M þ 11 had more than 200 CD4 þ cells/ml. Median CD8 þ cell counts increased early after transplantation and were close to normal values at M þ 4 (Figure 1d ), leading to an inversed CD4/CD8 ratio throughout the study period (data not shown).
CD56 þ NK cell reconstitution (Figure 1e ) was rapid since the median counts was half normal limit at M þ 1.5, with 5/17 patients having normal counts at this time and median counts were within normal range at M þ 18. Median CD19 þ B-cell counts (Figure 1f) reached normal values at M þ 11 and further increased at M þ 18.
Reconstitution of activated and naïve CD8 þ T cells
Activated CD8 þ cells were monitored following RIC-PBSCT using two cell surface activation markers: CD57 and HLA-DR. Median CD8 þ /CD57 þ (Figure 2a) as well as CD8 þ /HLA-DR þ (Figure 2b ) cell counts were normalized at M þ 1.5 and persisted within normal range, or were even over-represented, throughout the study period. The repartition of naı¨ve (CD45RA þ /CD27 þ ), early memory (CD45RAÀ/CD27 þ ), late memory (CD45RAÀ/CD27À) and effector (CD45RA þ /CD27À) CD8 þ T cells was analyzed using four-color flow cytometry. CD8 þ T cells expressed mainly a naı¨ve (Figure 2c ), early memory (Figure 2c ) or effector phenotype (Figure 2d ), while late memory cells were poorly represented (Figure 2d) . We further analyzed the expression of CD28 within naı¨ve, memory and effector cells. We observed that, while naı¨ve cells are expected to be 480% CD28 þ , 25 the median percentage of CD28 expression by such cells is low (20-50%) in transplanted patients and is even below the CD28 expression level of early memory cells (50-70%; Figure 2e ). As expected, 25 CD27À/CD8 þ (late memory and effector) T cells did not express the CD28 marker (data not shown).
Analysis of the thymic-dependent CD4 þ T-cell recovery
As shown in Figure 1c , CD4 þ T-cell recovery occurred late after transplantation. The repartition of naı¨ve and memory CD4 þ T cells was analyzed according to the expression of the CD45RA and CD45RO markers. Throughout the study, naı¨ve (CD45RA þ /CD45ROÀ) CD4 þ T cells were almost undetectable, while usually more than 80% of cells exhibited a CD45RAÀ/CD45RO þ memory phenotype, with the remaining cells being (Figure 3a) . We quantified the TREC contents within PBMC of 16 patients (median age: 53 (29-65) years) at M þ 7.5 and also, for nine of these 16 patients at M þ 11, that is, at a time of expected complete donor chimerism, and compared them to the TREC contents of 19 HSC donors (median age: 50 (27-66) years). Cells from 20 young adults (median age: 19 (18-22) years) were used as a positive control for TREC contents and had similar contents (median: 99.2 copies/10 6 GAPDH copies) as HSC donors (median: 81.4 copies/10 6 GAPDH copies). As shown Figure 3b , the TREC content in patients' PBMC was lower at M þ 7.5 (median: 21.5 copies/10 6 GAPDH copies, n ¼ 16), and even more at 11 months (median: 5.9 copies/10 6 GAPDH copies, n ¼ 9), than in the HSC donors (median: 81.4 copies/10 6 GAPDH copies, n ¼ 19). The difference was significant when comparing recipients with their respective donors (P ¼ 0.034 at M þ 7.5, n ¼ 16; P ¼ 0.004 at M þ 11, n ¼ 9; Wilcoxon's signed rank test). Linear regressions revealed no correlation between TREC content and donor or recipient age, number of infused CD34 þ cells or percent donor chimerism at M þ 7.5 or þ 11 (data not shown) and no association was found between TREC content and GvHD occurrence or DLI administration (Student's t-test; data not shown).
Discussion
Immune recovery after HSC transplantation is a dynamic process, modulated or influenced by various clinical factors such as GvHD occurrence or the age of the patient, 26, 27 and treatment-related factors such as immunosuppressive regimen or DLI. We studied the immune reconstitution after RIC-PBSCT in a group of patients homogeneous in age and type of hematopoietic stem cells, two factors possibly affecting T-cell recovery. Pathology and pre-and post transplant regimen were heterogeneous, as the study was The quantification of the episomal DNA by-products of thymic TCR rearrangement (termed TREC) is an available and accurate measure of thymic-dependent T-cell lymphopoiesis, 28 which has been correlated with the frequency of naı¨ve CD4 þ /CD45RA þ /CD45ROÀ 29 cells. We measured recipients' TREC levels between M þ 7.5 and M þ 11 after RIC-PBSCT, as chimerism during the same period was almost complete in our series, thus allowing an easier analysis of donor thymopoiesis. We observed a profound and prolonged CD3 þ /CD4 þ lymphopenia after RIC-PBSCT, which is emphasized by low naı¨ve CD4 þ /CD45RA þ /CD45ROÀ T-cell counts and low TREC levels. The predominant circulating CD4 þ T cells exhibited a memory CD4 þ /CD45RO þ /CD45RAÀ phenotype with the remaining cells expressing a CD45RA þ / CD45RO þ intermediate phenotype that has been associated with recently activated cells. 30 These memory and intermediate phenotypes suggest that most cells were recently activated and/or may result from peripheral expansion of infused donors T cells. It is possible that the reduction of median TREC levels observed between M þ 7.5 and M þ 11 could be due to the low number of patients, but we can also hypothesize that this reduction may result either from activation-induced cell death of naı¨ve cells or, more probably, from dilution of the TRECpositive cells, through peripheral naı¨ve T-cell division.
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This result is in line with data from Bahceci et al, 32 who observed a progressive decrease of TREC contents from day 14 to day 180 after RIC-PBSCT and concluded that early reconstitution resulted from post-thymic T-cell expansion. Our data further suggest that recent thymic emigrants may enter a peripheral expansion that would be added to the initial peripheral expansion of infused T cells.
In accordance with other studies, 17, 33 CD8 T cells normalized rapidly during the first months post transplantation as well. Most of the CD8 þ T cells were early memory CD8 þ /CD27 þ /CD45RAÀ and CD8 þ /CD27À/ CD45RA þ effectors T cells. These CD8 þ T cell subsets are described to be consecutive to clonal peripheral antigeninduced expansion. 34 A high frequency of cells also exhibited a CD8 þ /CD27 þ /CD45RA þ phenotype corresponding to naı¨ve CD8 þ T cells. This subset, supposed to be CD28 þ , 25 expressed unexpectedly low levels of CD28, suggesting that these so-called naı¨ve T cells may have entered an activation and/or differentiation process. We found rapid normalization or even overexpression of activated CD8 þ cells expressing CD57 or HLA-DR in the first months post transplantation. Early CD8 þ T-cell restoration led to a reversed CD4/CD8 ratio after RIC-PBSCT and may result from an initial expansion of transferred or residual CD8 þ T cells, as described by Rowbottom et al. 35 Biological activity of CD8 þ /CD57 þ cells is unclear, but is supposed to contain anti-CMV cytotoxic T cells. 35, 36 CD8 High /CD57 þ T cells arise from peripheral expansion and contribute to the oligoclonal antigen-dependent repertoire, while CD8 Low /CD57 þ are corresponding to NK cells, a cell subset also rapidly reconstituted in our study as usually observed after HSCT. 27 In agreement with previous studies, 20,37,38 we observed rapid NK cell reconstitution, since the median CD3À CD56 þ cell counts were close to the normal values as soon as M þ 1.5.
In our study, CD19 þ B cells seem to reconstitute more rapidly than CD4 þ T cells. In contrast to three studies 20, 37, 38 reporting B-cell reconstitutions (with similar kinetics as our study, that is, low B-cell counts until M þ 7.5 and normal values reached thereafter, 1 year after transplantation) in a context of early high CD4 T-cell counts, we noticed B-cell reconstitution despite long-lasting low CD4 T-cell counts. Low CD4 (helper) T-cell counts may lead to a weaker T-B cooperation and contribute to the lower extensive cGvHD incidence in our study than in these three studies.
Since both NK and B cells are also involved in the control of viral infections, their rapid reconstitution may contribute to a protective effect against viral reactivations after RIC-HSCT. Overall infectious complication rate in our group is very low compared to other studies investigating RIC-HSCT. 8, 39, 40 This may be due to the fact that our study was retrospectively conducted and that some infections may not have been documented and may have been treated at home by per os antibiotherapy. Despite a high rate of acute GvHD (60%) requiring corticosteroids and increasing the fungal infection risk, no invasive fungal infection (IFI) was observed in our series even in the case of patient 16, who had a previous IFI history. Hagen et al 8 have described 32% of IFIs (the majority being aspergillus infections), mainly after day 100, in RIC-PBSCT recipients at high risk for IFIs requiring high-dose corticosteroids. These data were at variance with other studies in the setting of RIC-HSCT. 40 The low number of infections in our cohort could result from the low occurrence of extensive cGVHD and, therefore, from a low need for prolonged steroid treatment. In a similar way, we observed only three patients with asymptomatic CMV antigenemia (15%) and no CMV disease. Moreover, these viral complications occurred early after RIC-PBSCT (before day 100). We observed similar incidence of CMV antigenemia (20.9%) and/or positive serum CMV PCR with a similar median time of incidence (60 days; range: 23-152) after conventional bone marrow transplantation during the same period of follow-up. Studies on CMV reactivation after RIC-HSCT described more frequent CMV antigenemia (40% 44 to 65%
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). The use of PBSC as a graft source, 41 as in our study, and a rapid reconstitution of CD8 þ T cells, especially CMV-specific CD8 þ T cells circulating within the first 3 months post transplant, 42 are two factors known to reduce the cumulative incidence of CMV positive antigenemia as compared with RIC-bone marrow transplantation.
In conclusion, our study suggests large peripheral T-cell expansion may compensate for a late thymic-dependent lymphopoiesis. Peripheral T-cell expansion and efficient NK and B-cell reconstitutions may contribute, with other factors such as careful anti-infectious prophylaxis and low incidence of cGvHD, to limit the severe infections, whose incidence was low in our series of RIC-PBSC-transplanted patients. However, given the low cohort analyzed in our study, further studies on larger series and longer follow-up periods are required to confirm these results.
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